Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%)

Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A

Quarterly Annual

Latest, Q1 2026

11.0%

Period ended Mar 31, 2026

Change on a year earlier

–

History

8 quarters

Since Q2 2021

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%)	Year on year	Source
Q1 2026	Mar 31, 2026	11.0%	–	Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025	Dec 31, 2025	23.0%	+27.0 pts	Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q4 2024	Dec 31, 2024	-4.0%	–	Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2023	Sep 30, 2023	4.0%	–	Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023	Jun 30, 2023	20.0%	–	Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023	Mar 31, 2023	15.0%	–	Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q3 2021	Sep 30, 2021	8.0%	–	Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021	Jun 30, 2021	20.0%	–	Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗

Cite this data

StockData. (2026). Amgen Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%), quarterly Q2 2021–Q1 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_vectibix_vol

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.